Pfs25 malaria vaccine - MVI

Drug Profile

Pfs25 malaria vaccine - MVI

Alternative Names: Malaria transmission-blocking Pfs25-Pfs25 conjugate vaccine; Pfs25 antigen; Pfs25 EPA; Pfs25 Pfs25; Pfs25 VLP; Pfs25 VLP-FhCMB; Pfs25-EPA/Alhydrogel; Transmission-blocking malaria vaccine - iBio/Fraunhofer

Latest Information Update: 28 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Johns Hopkins Bloomberg School of Public Health; Malaria Vaccine Initiative; Sabin Vaccine Institute
  • Developer Fraunhofer USA Center for Molecular Biotechnology; National Institute of Allergy and Infectious Diseases
  • Class Antimalarials; Parasitic vaccines; Vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Malaria

Most Recent Events

  • 28 Jul 2018 No recent reports of development identified for phase-I development in Malaria(Prevention) in Mali (Parenteral)
  • 28 Jul 2018 No recent reports of development identified for phase-I development in Malaria(Prevention, In volunteers) in USA (Parenteral)
  • 20 Dec 2016 National Institute of Allergy and Infectious Diseases (NIAID) completes a phase I trial in Malaria (Prevention) in Mali (NCT01867463)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top